Merck & Co Inc
NYSE:MRK

Watchlist Manager
Merck & Co Inc Logo
Merck & Co Inc
NYSE:MRK
Watchlist
Price: 100.89 USD -1.35% Market Closed
Market Cap: 250.4B USD
Section:
 

Relative Value

The Relative Value of one MRK stock under the Base Case scenario is hidden USD. Compared to the current market price of 100.89 USD, Merck & Co Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MRK Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

3.9
P/S
P/S
Price to Sales
3.9
vs History
61
vs Industry
33
Median 3Y
4.3
Median 5Y
4
Industry
2.6
Forward
3.8
More Details
13.2
P/E
P/E
Price to Earnings
13.2
vs History
80
vs Industry
33
Median 3Y
20.6
Median 5Y
20.6
Industry
21.8
Forward
11.2
More Details
14.7
P/OCF
P/OCF
Price to OCF
14.7
vs History
41
vs Industry
32
Median 3Y
14.7
Median 5Y
14.3
Industry
16.7
More Details
16.9
P/FCFE
P/FCFE
Price to FCFE
16.9
vs History
55
vs Industry
26
Median 3Y
17.4
Median 5Y
17.4
Industry
22.7
More Details
4.8
P/B
P/B
Price to Book Value
4.8
vs History
74
vs Industry
14
Median 3Y
5.8
Median 5Y
5.6
Industry
2.3
More Details
4.2
EV/S
EV/S
Enterprise Value to Sales
4.2
vs History
66
vs Industry
31
Median 3Y
4.7
Median 5Y
4.4
Industry
2.9
Forward
4.2
More Details
5.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.4
vs History
82
vs Industry
41
Median 3Y
6.4
Median 5Y
6.3
Industry
5.5
More Details
9.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
9.4
vs History
82
vs Industry
35
Median 3Y
11.3
Median 5Y
11.3
Industry
13
Forward
9
More Details
11.1
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
11.1
vs History
80
vs Industry
35
Median 3Y
13.4
Median 5Y
13.4
Industry
16.6
Forward
10
More Details
16
EV/OCF
EV/OCF
Enterprise Value to OCF
16
vs History
47
vs Industry
30
Median 3Y
16.1
Median 5Y
15.8
Industry
15.8
More Details
20.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
20.9
vs History
53
vs Industry
25
Median 3Y
20.9
Median 5Y
21.1
Industry
19.1
More Details
2.5
EV/IC
EV/IC
Enterprise Value to IC
2.5
vs History
49
vs Industry
29
Median 3Y
3
Median 5Y
2.5
Industry
1.9
More Details

Multiples Across Competitors

MRK Competitors Multiples
Merck & Co Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Merck & Co Inc
NYSE:MRK
250.9B USD 3.9 13.2 9.4 11.1
US
Eli Lilly and Co
NYSE:LLY
959.5B USD 16.1 52.1 35 37.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
487.2B USD 5.3 19.4 15.9 20.6
CH
Roche Holding AG
SIX:ROG
246.8B CHF 4 26.2 11.8 13.3
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP 4.8 29.7 108 158
CH
Novartis AG
SIX:NOVN
205.1B CHF 4.6 17.7 11.3 14.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.3 13.1 9.2 10.7
IE
Endo International PLC
LSE:0Y5F
202.5B USD 87.3 -69.3 321.2 805.4
US
Pfizer Inc
NYSE:PFE
146.1B USD 2.3 14.9 7.6 10.3
FR
Sanofi SA
PAR:SAN
102.9B EUR 1.5 7.5 6.8 6.8
P/E Multiple
Earnings Growth PEG
US
Merck & Co Inc
NYSE:MRK
Average P/E: 21.5
13.2
15%
0.9
US
Eli Lilly and Co
NYSE:LLY
52.1
50%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.4
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.2
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.7
38%
0.8
CH
Novartis AG
SIX:NOVN
17.7
18%
1
DK
Novo Nordisk A/S
CSE:NOVO B
13.1
7%
1.9
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
31%
0.5
FR
Sanofi SA
PAR:SAN
7.5
26%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Merck & Co Inc
NYSE:MRK
Average EV/EBITDA: 398.4
9.4
7%
1.3
US
Eli Lilly and Co
NYSE:LLY
35
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
15.9
8%
2
CH
Roche Holding AG
SIX:ROG
11.8
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108
10%
10.8
CH
Novartis AG
SIX:NOVN
11.3
6%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
9.2
6%
1.5
IE
E
Endo International PLC
LSE:0Y5F
321.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
FR
Sanofi SA
PAR:SAN
6.8
9%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Merck & Co Inc
NYSE:MRK
Average EV/EBIT: 1 708.2
11.1
9%
1.2
US
Eli Lilly and Co
NYSE:LLY
37.5
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.6
14%
1.5
CH
Roche Holding AG
SIX:ROG
13.3
6%
2.2
UK
AstraZeneca PLC
LSE:AZN
158
22%
7.2
CH
Novartis AG
SIX:NOVN
14.5
12%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
10.7
6%
1.8
IE
E
Endo International PLC
LSE:0Y5F
805.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
10%
1
FR
Sanofi SA
PAR:SAN
6.8
15%
0.5

See Also

Summary
MRK intrinsic value, competitors valuation, and company profile.
DCF Valuation
MRK stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MRK stock valuation using valuation multiples.
Wall Street Estimates
MRK price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MRK stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 300,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.